Enlicitide is an oral macrocyclic PCSK9 inhibitor peptide. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Enlicitide has an FDA-approved product on the U.S. market, marketed as Lipfendra Tablet, Film Coated [Merck Sharp & Dohme Llc].
The current label is held by Merck Sharp & Dohme LLC.
The evidence
2 sources on Enlicitide, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Enlicitide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides